IP Library Granted Patent US 10,677,783
Granted Patent B2
US 10,677,783 · App. 14/431,986 · Granted Jun 9, 2020

Method for evaluating effect of cytokine on metabolic activity of cytochrome P450, and drug screening method

Inventors: Kaoru Kobayashi (Chiba, JP); Hanaka Mimura (Chiba, JP); Kan Chiba (Chiba, JP); Yoko Ejiri (Kurashiki, JP); Masaya Hosoda (Kurashiki, JP); Satoru Ayano (Kurashiki, JP)
Assignee: Corning Incorporated
G01N33/5041C12Q1/26C12Q1/6876G01N33/5073G01N33/573C12Q2600/136C12Q2600/158G01N2333/485G01N2333/525G01N2333/5412G01N2333/80G01N2500/04G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,677,783
App. No.
14/431,986
Granted
Jun 9, 2020
Kind
B2
Abstract

Provided is a technique that uses an established hepatocyte cell line in a method for evaluating an effect of a cytokine on a metabolic activity of a cytochrome P450 and in a method for evaluating a drug which interacts with a cytokine. The method for evaluating an effect of a cytokine on a metabolic activity of a cytochrome P450 includes: culturing an established hepatocyte cell line by using a culture chamber ( 10 ) including culture rooms ( 11 ), to thereby form spheroids ( 9 ); and evaluating the presence or absence of induction or attenuation of the cytochrome P450 after bringing a spheroid-shaped established hepatocyte cell line into contact with a test solution containing the cytokine in the culture chamber for one hour or more and less than 96 hours.

Claims (16)

1. A method for screening a drug which interacts with a cytokine, comprising:

preparing a first test solution containing neither the cytokine nor the drug, a second test solution containing the cytokine and not containing the drug, and a third test solution containing both the cytokine and the drug;

seeding, in each well of a culture plate having at least one well, cells of an established hepatocyte cell line in a culture medium, wherein each well of the culture plate has a plurality of culture rooms;

culturing the cells of the established hepatocyte cell line and forming, in at least one of the plurality of culture rooms in each well, a spheroid of the cells;

removing the culture medium from each well;

adding one of the first test solution, the second test solution, or the third test solution to each well;

bringing one of the first test solution, the second test solution, or the third test solution into contact with the spheroid of the established hepatocyte cell line in at least one culture room in each well for one hour or more and less than 96 hours, wherein adding the first test solution, the second test solution, or the third test solution to each well brings the first test solution, the second test solution, or the third test solution into contact with the spheroid(s) in each well to which the first test solution, the second test solution, or the third test solution has been added;

obtaining a first measurement value of cytochrome P450 by measuring a value of a cytochrome P450 of the established hepatocyte cell line brought into contact with the first test solution, and obtaining second and third measurement values of cytochrome P450 by measuring the value of the cytochrome P450 of the established hepatocyte cell line brought into contact with the second and third test solutions, respectively, wherein measuring the value of the cytochrome P450 comprises measuring a value selected from the group consisting of a metabolic activity level of cytochrome P450 in the cell, a gene expression level of cytochrome P450 in the cell, an amount of cytochrome P450 protein in the cell, and combinations thereof; and

determining that the drug restores a drug-metabolizing function of the cytochrome P450, when the first measurement value is greater than the second measurement value and the third measurement value is three times greater than the second measurement value;

wherein the third test solution contains the drug at a concentration at which a survival rate of the spheroid of the established hepatocyte cell is more than 80%, when the established hepatocyte cell is brought into contact with the drug at the concentration in a range from one hour to 96 hours;

wherein each culture room has an equivalent diameter in a range from 50 μm to 500 μm, which is a range equal to or more than 1 times to 5 times the diameter of the spheroid of the established hepatocyte cell line in the culture room, a height that is 0.3 to 1 times the equivalent diameter, a contact angle of a culture surface equal to or less than 45 degrees, and walls partitioning the culture room with each wall having a width in the range of 2 μm to 50 μm;

wherein an average value of a diameter of the spheroid of the established hepatocyte cell line formed in a culture room is equal to or more than 50 μm and less than 200 μm; and

wherein a number N 2 is a number of spheroids included in all spheroids present in one well, wherein considering a correlation between a size of a diameter of each spheroid and the number of existing spheroids, the number N 2 is a number of spheroids present in a range from a minimum diameter D 2 to a maximum diameter D 3 among a plurality of diameters corresponding to half of a number N 1 (N 1 /2), wherein the number N 1 is a number of the existing spheroids included in all the spheroids present in the one well and having a diameter D 1 , and the number N 2 of spheroids accounts for 70% or more of the total number of spheroids in the one well.

2. The screening method according to claim 1 , wherein a solvent for the test solution is a serum-free culture medium.

3. The screening method according to claim 1 , wherein a concentration of the cytokine of the second and third test solutions is selected from among at least three concentrations of the cytokine at which the second measurement value of cytochrome P450 is smaller than the first measurement value of cytochrome P450, and wherein the at least three concentrations of the cytokine are being equal to a reference concentration, 10 times higher than the reference concentration, and 100 times higher than the reference concentration, respectively, the reference concentration being a cytokine concentration in a range from equal to or more than 0.1 times higher to 50 times higher than a blood level of the cytokine secreted from a patient with a disease.

4. The screening method according to claim 1 , wherein in forming the spheroid, the culture medium contains 10% serum.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2018
From: KURARAY CO., LTD.
To: CORNING INCORPORATED
Reel/Frame 047843/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2015
From: KOBAYASHI, KAORU; MIMURA, HANAKA; CHIBA, KAN; EJIRI, YOKO; HOSODA, MASAYA; AYANO, SATORU
To: KURARAY CO., LTD.
Reel/Frame 035275/0193 →
Priority Claims (2)
JP 2012-213977 · Sep 27, 2012 · national
JP 2012-213978 · Sep 27, 2012 · national
Continuity (1)
Related Publication 20150276716A1 · Oct 1, 2015